Design, synthesis, and biological evaluation of new biaryl derivatives of cycloalkyl diacetamide bearing chalcone moiety as type II c-MET kinase inhibitors.
Anticancer
Chalcone
Dicarboxamide
Tubulin polymerization
c-MET Kinase
Journal
Molecular diversity
ISSN: 1573-501X
Titre abrégé: Mol Divers
Pays: Netherlands
ID NLM: 9516534
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
27
06
2023
accepted:
05
01
2024
medline:
11
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
aheadofprint
Résumé
Many human cancers have been associated with the deregulation of the mesenchymal-epithelial transition factor tyrosine kinase (MET) receptor, a promising drug target for anticancer drug discovery. Herein, we report the discovery of a novel structure of potent chalcone-based derivatives type II c-Met inhibitors which are comparable to Foretinib (IC
Identifiants
pubmed: 38466553
doi: 10.1007/s11030-024-10807-x
pii: 10.1007/s11030-024-10807-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Tehran University of Medical Sciences
ID : 55283
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Eder JP et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15(7):2207–2214. https://doi.org/10.1158/1078-0432
doi: 10.1158/1078-0432
pubmed: 19318488
Goetsch L, Caussanel V, Corvaia N (2013) Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Front Biosci 18(2):454–473
doi: 10.2741/4114
O’toole, J.M., et al (2006) Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66(18):9162–9170
doi: 10.1158/0008-5472.CAN-06-0283
pubmed: 16982759
Organ SL, Tsao M-S (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol. https://doi.org/10.1177/1758834011422556
doi: 10.1177/1758834011422556
pubmed: 22128289
pmcid: 3225017
Zhang Y et al (2018) Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17(1):1–14. https://doi.org/10.1186/s12943-018-0796-y
doi: 10.1186/s12943-018-0796-y
pubmed: 29304823
pmcid: 5755155
Liang D et al (2022) Discovery of small-molecule fluorescent probes for C-Met. Eur J Med Chem. https://doi.org/10.1016/j.ejmech.2022.114114
doi: 10.1016/j.ejmech.2022.114114
pubmed: 36577214
pmcid: 8933873
Parikh PK, Ghate MD (2018) Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur J Med Chem 143:1103–1138. https://doi.org/10.1016/j.ejmech.2017.08.044
doi: 10.1016/j.ejmech.2017.08.044
pubmed: 29157685
Birchmeier C et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915–925. https://doi.org/10.1038/nrm1261
doi: 10.1038/nrm1261
pubmed: 14685170
Mohyeldin MM et al (2016) Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. Eur J Med Chem 118:299–315. https://doi.org/10.1016/j.ejmech.2016.04.043
doi: 10.1016/j.ejmech.2016.04.043
pubmed: 27258622
pmcid: 5073051
Yuan H et al (2018) Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors. Eur J Med Chem 143:491–502
doi: 10.1016/j.ejmech.2017.11.073
pubmed: 29202410
Dharmawardana PG, Giubellino A, Bottaro DP (2004) Hereditary papillary renal carcinoma type I. Curr Mol Med 4(8):855–868. https://doi.org/10.2174/1566524043359674
doi: 10.2174/1566524043359674
pubmed: 15579033
Wang Z et al (2020) Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3, 4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors. Bioorg Chem. https://doi.org/10.1016/j.bioorg.2020.104371
doi: 10.1016/j.bioorg.2020.104371
pubmed: 33453645
pmcid: 7686041
El-Wakil MH, Teleb M (2021) Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1, 3, 4-thiadiazolo [2, 3-c]-1, 2, 4-triazin-4-one derivatives. Bioorg Chem. https://doi.org/10.1016/j.bioorg.2021.105304
doi: 10.1016/j.bioorg.2021.105304
pubmed: 34534756
Ibrahim HS et al (2019) Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase. Bioorg Chem 85:337–348. https://doi.org/10.1016/j.bioorg.2019.01.006
doi: 10.1016/j.bioorg.2019.01.006
pubmed: 30658233
Puccini A et al (2019) Safety and tolerability of c-MET inhibitors in cancer. Drug Saf 42:211–233. https://doi.org/10.1007/s40264-018-0780-x
doi: 10.1007/s40264-018-0780-x
pubmed: 30649748
pmcid: 7491978
Mo H-N, Liu P (2017) Targeting MET in cancer therapy. Chronic Dis Transl Med. 3(03):148–153
pubmed: 29063069
pmcid: 5643781
Katayama R et al (2013) Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 73(10):3087–3096. https://doi.org/10.1158/0008-5472.CAN-12-3256
doi: 10.1158/0008-5472.CAN-12-3256
pubmed: 23598276
pmcid: 3759033
Best J et al (2017) Tivantinib for the treatment of hepatocellular carcinoma. Expert Opin Pharmacother 18(7):727–733. https://doi.org/10.1080/14656566.2017.1316376
doi: 10.1080/14656566.2017.1316376
pubmed: 28414564
Rimassa L et al (2018) Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 19(5):682–693. https://doi.org/10.1016/S1470-2045(18)30146-3
doi: 10.1016/S1470-2045(18)30146-3
pubmed: 29625879
Adjei AA, Schwartz B, Garmey E (2011) Early clinical development of ARQ 197, a Selective, Non–ATP-competitive inhibitor targeting MET Tyrosine kinase for the treatment of advanced cancers. Oncologist 16(6):788–799. https://doi.org/10.1634/theoncologist.2010-0380
doi: 10.1634/theoncologist.2010-0380
pubmed: 21632449
pmcid: 3228218
Goldman JW et al (2012) Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118(23):5903–5911. https://doi.org/10.1002/cncr.27575
doi: 10.1002/cncr.27575
pubmed: 22605616
Shuai W et al (2021) Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy. J Med Chem 64(12):7963–7990. https://doi.org/10.1021/acs.jmedchem.1c00100
doi: 10.1021/acs.jmedchem.1c00100
pubmed: 34101463
Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9(10):790–803. https://doi.org/10.1038/nrd3253
doi: 10.1038/nrd3253
pubmed: 20885410
pmcid: 3194401
Yang C-PH, Horwitz SB (2017) Taxol®: the first microtubule stabilizing agent. Int J Mol Sci 18(8):1733. https://doi.org/10.3390/ijms18081733
doi: 10.3390/ijms18081733
pubmed: 28792473
pmcid: 5578123
Campiani G et al (2022) Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy. Eur J Med Chem 235:114274. https://doi.org/10.1016/j.ejmech.2022.114274
doi: 10.1016/j.ejmech.2022.114274
pubmed: 35344902
Steinmetz MO, Prota AE (2018) Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol 28(10):776–792. https://doi.org/10.1016/j.tcb.2018.05.001
doi: 10.1016/j.tcb.2018.05.001
pubmed: 29871823
Liang T et al (2022) Combination of microtubule targeting agents with other antineoplastics for cancer treatment. Biochim Biophys Acta Rev Cancer. https://doi.org/10.1016/j.bbcan.2022.188777
doi: 10.1016/j.bbcan.2022.188777
pubmed: 35963551
Serpico AF, Visconti R, Grieco D (2020) Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death Dis 11(5):1–7. https://doi.org/10.1038/s41419-020-2567-0
doi: 10.1038/s41419-020-2567-0
Cao Y-N et al (2018) Recent advances in microtubule-stabilizing agents. Eur J Med Chem 143:806–828
doi: 10.1016/j.ejmech.2017.11.062
pubmed: 29223097
Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10(3):194–204. https://doi.org/10.1038/nrc2803
doi: 10.1038/nrc2803
pubmed: 20147901
Zhu H et al (2020) Design, synthesis and biological evaluation of vinyl selenone derivatives as novel microtubule polymerization inhibitors. Eur J Med Chem 207:112716. https://doi.org/10.1016/j.ejmech.2020.112716
doi: 10.1016/j.ejmech.2020.112716
pubmed: 32853870
Rosini M (2014) Polypharmacology: the rise of multitarget drugs over combination therapies. Future Med Chem 6(5):485–487. https://doi.org/10.4155/fmc.14.25
doi: 10.4155/fmc.14.25
pubmed: 24649950
Talevi A (2015) Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front pharmacol 6:205. https://doi.org/10.3389/fphar.2015.00205
doi: 10.3389/fphar.2015.00205
pubmed: 26441661
pmcid: 4585027
L Bolognesi, M., Polypharmacology in a single drug: multitarget drugs. Curr. Med. Chem., 2013. 20(13): p. 1639–1645
Arnst KE et al (2019) Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Med Res Rev 39(4):1398–1426. https://doi.org/10.1002/med.21568
doi: 10.1002/med.21568
pubmed: 30746734
pmcid: 6857175
Tanabe K (2017) Microtubule depolymerization by kinase inhibitors: unexpected findings of dual inhibitors. Int J Mol Sci 18(12):2508. https://doi.org/10.3390/ijms18122508
doi: 10.3390/ijms18122508
pubmed: 29168788
pmcid: 5751111
Tian C et al (2022) Discovery of (2-(pyrrolidin-1-yl) thieno [3, 2-d] pyrimidin-4-yl)(3, 4, 5-trimethoxyphenyl) methanone as a novel potent tubulin depolymerizing and vascular disrupting agent. Eur J Med Chem. https://doi.org/10.1016/j.ejmech.2022.114466
doi: 10.1016/j.ejmech.2022.114466
pubmed: 36395649
Kim DY et al (2006) Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem 49(19):5664–5670. https://doi.org/10.1021/jm050761i
doi: 10.1021/jm050761i
pubmed: 16970393
Bellon SF et al (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 283(5):2675–2683. https://doi.org/10.1074/jbc.M705774200
doi: 10.1074/jbc.M705774200
pubmed: 18055465
D’Angelo ND et al (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors. J Med Chem 51(18):5766–5779. https://doi.org/10.1021/jm8006189
doi: 10.1021/jm8006189
pubmed: 18763753
Zhu W et al (2016) Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo [2, 3-b] pyridine moiety as c-Met inhibitors. Bioorg Med Chem 24(8):1749–1756. https://doi.org/10.1016/j.bmc.2016.02.046
doi: 10.1016/j.bmc.2016.02.046
pubmed: 26964675
Nakagawa T et al (2010) E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 101(1):210–215. https://doi.org/10.1111/j.1349-7006.2009.01343.x
doi: 10.1111/j.1349-7006.2009.01343.x
pubmed: 19832844
Kataoka Y et al (2012) Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 30(4):1352–1360. https://doi.org/10.1007/s10637-011-9699-0
doi: 10.1007/s10637-011-9699-0
pubmed: 21655918
Koziel R et al (2010) Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. J Physiol Pharmacol 61(2):233
pubmed: 20436225
Aranha O et al (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22(4):787–794. https://doi.org/10.3892/ijo.22.4.787
doi: 10.3892/ijo.22.4.787
pubmed: 12632069
Toolabi M et al (2022) Synthesis of novel 2-acetamide-5-phenylthio-1, 3, 4-thiadiazole-containing phenyl urea derivatives as potential VEGFR-2 inhibitors. Arch Pharm 355(3):2100397. https://doi.org/10.1002/ardp.202100397
doi: 10.1002/ardp.202100397
Mohammadian E et al (2022) Thienopyrimidine-based agents bearing diphenylurea Design, synthesis, and evaluation of antiproliferative and antiangiogenic activity. Arch Pharm. https://doi.org/10.1002/ardp.202200349
doi: 10.1002/ardp.202200349
Wang B et al (2019) Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors. Bioorg Med Chem Lett 29(18):2638–2645. https://doi.org/10.1016/j.bmcl.2019.07.045
doi: 10.1016/j.bmcl.2019.07.045
pubmed: 31400938
Li L et al (2018) Pt (IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. Eur J Med Chem 156:666–679. https://doi.org/10.1016/j.ejmech.2018.07.016
doi: 10.1016/j.ejmech.2018.07.016
pubmed: 30031977